<DOC>
	<DOCNO>NCT01539590</DOCNO>
	<brief_summary>The study evaluate effect BB3 preserve myocardial ( heart ) tissue function follow myocardial infarction ( heart attack ) .</brief_summary>
	<brief_title>Study Evaluate Safety Activity BB3 Treat Heart Attack</brief_title>
	<detailed_description>Percutaneous coronary intervention ( PCI ) become mainstay treatment ST-segment elevation myocardial infarction ( STEMI ) . Whereas early recanalization undoubtedly salvage myocardial tissue , reperfusion follow prolonged ischemia also exacerbate injury . Infarct size need limit , condition favor adaptive ventricular heal remodel optimized patient acute myocardial infarction ( AMI ) die out-of-hospital arrhythmia , long-term prognosis dependent amount myocardium lose , outcome ventricular remodeling . Angion Biomedical Corp. identify BB3 , small molecule mimetic hepatocyte growth factor/scatter factor ( HGF/SF ) whose activity expect preserve tissue viability attenuate dysfunction set organ injury obviate logistical difficulty associate gene protein therapy . HGF/SF naturally occur cell survival factor hold significant therapeutic potential . BB3 show posse HGF/SF activity , include protection heart injury follow myocardial infarction . This study design evaluate clinical efficacy BB3 patient present acute ST segment elevation myocardial infarction ( A-STEMI ) undergo PCI .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>1 . The subject legally authorize representative inform nature study , agree provision , provide sign write informed consent , approve Institutional Review Board ( IRB ) , prior performance study related procedure include screening procedure . 2 . Subject male female 3 . Subject 21 80 year age 4 . Estimated body weight &lt; 120 kg BMI &lt; 40 5 . Subject experience clinical symptom consistent acute myocardial infarction ( AMI ) ( e.g. , chest pain , arm pain , etc. , ) &gt; 30 minute duration unresponsive nitroglycerin ; ST segment elevation 1 mm least two contiguous lead ECG new presume new onset bundle branch block ( BBB ) 6 . Fulfills clinical center 's criterion primary PCI 7 . PCI do within 12 hour onset STEMI . 8 . The subject his/her physician willing comply requirement study specify followup evaluation . 9 . If female , either surgically sterile postmenopausal use acceptable contraception agree use effective birth control regimen study period . Men must agree use condom study period . Women child bear potential must negative urine serum pregnancy test . 10 . In opinion Investigator , subject capable understanding comply protocol . 1 . Pregnant nursing subject plan pregnancy period 6 month follow index procedure . 2 . Cardiogenic shock ( Killip class 4 ) cardiac arrest 3 . History prior myocardial infarction preexist Q wave ECG 4 . An elective surgical procedure plan would necessitate interruption antiplatelet agent first six month post enrollment ; 5 . Any contraindication undergo MRI imaging . This include follow exclusion : 1 . Cardiac pacemaker implantable defibrillator ; 2 . NonMRIcompatible aneurysm clip ; 3 . Neural stimulator ( e.g. , TENSUnit ) ; 4 . Any implanted magnetically activate device ( e.g. , insulin pump ) ; 5 . Any type nonMRIcompatible metallic ear implant ; 6 . Metal shaving orbit ; 7 . Any metallic foreign body , shrapnel , bullet location physician feel would present risk subject ; 8 . Any history indicate contraindication MRI , include claustrophobia allergy gadolinium ; 9 . Inability follow breathhold instruction maintain breathhold &gt; 15 second ; 10 . Irregular cardiac rhythm expect resolve treatment acute cardiac condition ( e.g. , chronic atrial fibrillation ) 11 . Known hypersensitivity contraindication gadolinium contrast . 6 . Subject active bleeding history bleed diathesis coagulopathy ( include heparin induce thrombocytopenia ) , refusal receive blood transfusion necessary ; 7 . Subjects present cardiogenic shock ( SBP &lt; 80 mmHg &gt; 30 minute , require IV pressor emergency IABP hypotension treatment ) cardiopulmonary resuscitation prior randomization ; 8 . History intracerebral mass , aneurysm , arteriovenous malformation , hemorrhagic stroke ; stroke transient ischemic attack within past 6 month , permanent residual neurologic defect ; know precede cardiac ventricular arrhythmia 9 . Impaired renal function ( eGFR ≤30 ml/min/1.73m2 , estimate MDRD4v equation ) dialysis . 10 . Impaired hepatic function ( ALT &gt; 2x upper limit normal , total bilirubin great 1.5 x upper limit normal ) . 11 . Currently participate participate investigational drug medical device study within 30 day 5 halflives , whichever longer , prior enrollment study 12 . Have active malignancy history solid , metastatic , hematologic malignancy exception basal squamous cell carcinoma skin remove 13 . History positive human immunodeficiency virus ( HIV ) test 14 . History rheumatoid arthritis 15 . History proliferative retinopathy laser surgery retinopathy 16 . Subjects require cytochrome P450 1A2 ( CYP1A2 ) inhibitor , ciprofloxacin and/or fluvoxamine ( Luvox® ) 17 . Subject medical illness know history substance abuse ( alcohol , cocaine , heroin etc . ) may cause noncompliance protocol , confound data interpretation associate limited life expectancy le 6 month , 18 . Any significant medical condition Investigator 's opinion may interfere subject 's optimal participation study ; 19 . Subject know hypersensitivity allergy stainless steel , nickel , cobalt chromium , nitinol , titanium know hypersensitivity allergy contrast medium ( e.g . rash ) effectively control premedication steroid and/or diphenhydramine . Subjects hypersensitivity allergy component device ( structural , drug polymer component ) subject true prior anaphylaxis contrast medium enrol</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>hepatocyte growth factor mimetic</keyword>
	<keyword>hepatocyte growth factor ( HGF )</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Acute ST Segment Elevation Myocardial Infarction ( STEMI )</keyword>
	<keyword>Percutaneous Coronary Intervention ( PCI )</keyword>
</DOC>